Mackenzie Financial
CRNX

Mackenzie Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Mackenzie Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,666
Closed -$268K – 1495
2025
Q4 		$268K Sell
5,666
-273
-5% -$12.2K ﹤0.01% 1428
2025
Q3 		$247K Buy
+5,939
New +$190K ﹤0.01% 1479
2025
Q1 		– Sell
-5,422
Closed -$277K – 1710
2024
Q4 		$277K Buy
5,422
+440
+9% +$24.6K ﹤0.01% 1418
2024
Q3 		$255K Buy
+4,982
New +$257K ﹤0.01% 1263
2023
Q3 		– Sell
-14,909
Closed -$269K – 1495
2023
Q2 		$269K Buy
+14,909
New +$297K ﹤0.01% 1207

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Mackenzie Financial's CRNX Position: Q1 2026 in Review

Mackenzie Financial sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 5,666 shares — an estimated $268K sold.

Mackenzie Financial first reported a position in CRNX in Q2 2023 and held it in 5 quarters. The position peaked at $277K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Mackenzie Financial reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mackenzie Financial sold 5,666 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $268K.
  • Mackenzie Financial first reported a position in Crinetics Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Mackenzie Financial's Crinetics Pharmaceuticals position peaked at $277K in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.